Kostakoglu Lale, Chauvie Stéphane
Nuclear Medicine and Molecular Imaging, Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1141, New York, NY 10029, USA.
Department of Medical Physics, 'Santa Croce e Carle' Hospital, Cuneo, Italy.
PET Clin. 2019 Jul;14(3):317-329. doi: 10.1016/j.cpet.2019.03.002.
Lymphoma is a potentially curable disease; however, the clinical challenge lies in further improvement of outcomes. PET with fludeoxyglucose is an effective imaging tool. PET-derived quantitative metrics have raised significant interest to be used as a prognostic factor to complement clinical parameters for treatment decisions. The most optimized use of these quantitative PET metrics, however, will be possible with the standardization of imaging procedures. In this article, we review the technical and methodological considerations related to PET-derived quantitative metrics, and the relevant published data to emphasize the potential value of these metrics in patient prognosis and treatment response in lymphoma.
淋巴瘤是一种潜在可治愈的疾病；然而，临床面临的挑战在于进一步改善治疗效果。氟脱氧葡萄糖正电子发射断层显像（PET）是一种有效的成像工具。PET衍生的定量指标已引起人们极大兴趣，有望作为一种预后因素，以补充临床参数用于治疗决策。然而，只有实现成像程序的标准化，才能最优化地使用这些PET定量指标。在本文中，我们回顾了与PET衍生定量指标相关的技术和方法学考量，以及相关已发表数据，以强调这些指标在淋巴瘤患者预后和治疗反应中的潜在价值。
